Stocks and Investing
Stocks and Investing
Tue, November 8, 2022
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Luca Issi Maintained (VERV) at Buy with Decreased Target to $35 on, Nov 8th, 2022
Luca Issi of RBC Capital, Maintained "Verve Therapeutics, Inc." (VERV) at Buy with Decreased Target from $42 to $35 on, Nov 8th, 2022.
Luca has made no other calls on VERV in the last 4 months.
There are 3 other peers that have a rating on VERV. Out of the 3 peers that are also analyzing VERV, 1 agrees with Luca's Rating of Hold. Following is the relevant analyst calls for the last 4 months
- Richard Law of "Credit Suisse" Initiated at Hold and Held Target at $48 on, Thursday, October 6th, 2022
These are the ratings of the 2 analyists that currently disagree with Luca
- Dae Gon Ha of "Stifel" Upgraded from Hold to Strong Buy and Increased Target to $56 on, Thursday, August 25th, 2022
- Kostas Biliouris of "BMO Capital" Maintained at Buy with Increased Target to $62 on, Monday, July 18th, 2022
Contributing Sources